- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06413069
Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON) (AGAMEMNON)
Effects of Almonds in Glucose-intolerant Adults - a Randomised Controlled Study on Muscle Mass and Obesity, Energy Metabolism and Lipidome, NON-alcoholic Fatty Liver and Inflammation (AGAMEMNON)
Tree nuts - such as almonds - contribute to beneficial effects of the Mediterranean diet on risk for cardiovascular events, type 2 diabetes, dyslipidemia, hypertension, inflammation and non-alcoholic fatty liver disease. Almonds provide few carbohydrates, but lots of unsaturated fat and dietary fiber. But to which extent and by which mechanisms may almonds improve all aspects of the Metabolic Syndrome? Previous clinical trials showed weaker effects than rodent studies, most possibly due to low statistical power and metabolically insusceptible patients.
The 3-year AGAMEMNON project aims to investigate, if 16 weeks of supplementation with almonds (vs. no treatment) in 150 patients with prediabetes and NAFLD leads to significant improvements in glycemia and liver fat, lipid metabolism, body composition and inflammation. The isocaloric design will outrule effects of weight loss and will allow the analysis of metabolic pathways between fat depots, inflammation, insulin resistance and gut function. Lipidomics are assessed as novel predictor of disease progression and metabolic response.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background / Significance:
T2D affects 5-10 % of the global population, challenging societies, health systems, economy and quality of life. Dietary treatment may avoid disease burdens, save money and protect general health resources, but is often limited to unspecific weight loss recommendations and advise for physical activity. Despite being the common advice, body weight reduction is faced with inconclusive evidence for its impact on long-term risks (obesity paradox?), lack of long-term compliance and irresponsive or ineligible subgroups of patients. The Mediterranean diet provides the ideal dietary composition and reduces CVD risk, improving every axis of the Metabolic Syndrome, including liver fat. It is unclear, though, to which extent tree nuts contribute to this effect.
In meta-analyses, almonds improve glycemia and lipids. Benefits on body composition and inflammation are also expected, these might extend to NAFLD.
n6-PUFAs (typical components of tree nuts) reduce T2D risk and liver fat in humans. This was shown for sunflower oil, but not yet for nuts. Evidence for NAFLD benefits by almonds in humans is limited to observational studies, post-hoc analyses of mixed interventions, and underpowered RCTs.
Aims / Rationale:
Nuts are safe for NAFLD patients. Previous data indicate, that almonds may elicit benefits on glycemia and liver fat in patients susceptible to this treatment.
Therefore, the investigators' project aims to investigate whole almonds as dietary treatment for glucose intolerance and NAFLD in patients with this typical combined phenotype. NAFLD independently predicts T2D progression and late complications. (Pre)diabetes patients with NAFLD are at higher risk for the entire metabolic syndrome and for early onset of nephropathy and CVD. On the other hand, prediabetes/T2D patients with NAFLD are also especially susceptible to lifestyle treatments. The investigators hypothesize to detect benefits of almonds with respect to glycemia and liver fat, but also lipid metabolism, body composition and inflammation compared to standard diet. Treatment period of 16 weeks is longer than earlier almond studies.
The investigators intend to show, that the metabolic improvement is independent from weight loss and, even in the opposite, supports maintenance of muscle mass. The research group wants to investigate mechanistic links between the metabolic pathways of visceral fat accumulation, inflammation, NAFLD, insulin resistance, dyslipidemia and the gut microbiome. Finally, the investigators aim to assess the lipidome (analysed from the erythrocyte membranes, full blood and plasma samples), which was recently established as a novel biomarker to predict disease progression, metabolic response and treatment-specific improvement.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stefan Kabisch, Dr. med.
- Phone Number: 429 0049-30-450514
- Email: stefan.kabisch@charite.de
Study Contact Backup
- Name: Felizitas Kalinowski
- Phone Number: 428 0049-30450514
- Email: felizitas.kalinowski@charite.de
Study Locations
-
-
-
Berlin, Germany, 12203
- Recruiting
- Charite University Hospital Berlin
-
Contact:
- Stefan Kabisch, Dr. med.
- Phone Number: 030 450 514 429
- Email: stefan.kabisch@charite.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- prediabetes (IFG or IGT or IFG-IGT), measured in plasma samples
- NAFLD (MR-S: >5,56 %)
- BMI between 25 and 40 kg/m²
Exclusion Criteria:
- Treatment with antidiabetic drugs
- Overt diabetes mellitus of any kind
- Severe cardiovascular or pulmonary disorder
- Renal disorder / Renal insufficiency (eGFR < 60 ml/min/m²)
- Severe psychiatric disorder (schizophrenia, severe depression; eating disorders)
- Current or recent (< 5 years) cancer diagnosis
- Liver disease other than NAFLD
- Use of corticosteroid treatments
- Alcohol abuse
- Smoking
- Ongoing or recently finished (3 months before) weight loss
- Current participation in other intervention studies
- Pregnancy
- Metal implants, claustrophobia
- Allergy to almonds
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Almond treatment
Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks.
|
Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks.
Patients of the no-nut group will receive 6,7 kgs of almonds after finishing the study, supporting their compliance as untreated group.
|
No Intervention: Control condition
Patients of the no-nut group will receive 6,7 kgs of almonds after completing 16 weeks of waiting time, supporting their compliance as untreated group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Liver fat content
Time Frame: 16 weeks
|
change in liver fat content (magnetic resonance spectroscopy)
|
16 weeks
|
concentration of fasting plasma glucose
Time Frame: 16 weeks
|
change in concentration of fasting plasma glucose
|
16 weeks
|
concentration of 2-h plasma glucose (75 g oGTT)
Time Frame: 16 weeks
|
change in concentration of 2-h plasma glucose (75 g oGTT)
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
whole body fat content (%; measured with BIA)
Time Frame: 16 weeks
|
change in whole body fat content
|
16 weeks
|
whole body fat content (kg; measured with BIA)
Time Frame: 16 weeks
|
change in whole body fat content
|
16 weeks
|
insulin sensitivity (Matsuda)
Time Frame: 16 weeks
|
change in insulin sensitivity (Matsuda)
|
16 weeks
|
blood pressure (sys/dia)
Time Frame: 16 weeks
|
change in blood pressure (sys/dia)
|
16 weeks
|
serum concentration of CRP
Time Frame: 16 weeks
|
change in serum concentration of CRP
|
16 weeks
|
serum concentration of IL-6
Time Frame: 16 weeks
|
change in serum concentration of IL-6
|
16 weeks
|
serum concentration of IL-10
Time Frame: 16 weeks
|
change in serum concentration of IL-10
|
16 weeks
|
serum concentration of IL-1ß
Time Frame: 16 weeks
|
change in serum concentration of IL-1ß
|
16 weeks
|
serum concentration of IL-18
Time Frame: 16 weeks
|
change in serum concentration of IL-18
|
16 weeks
|
serum concentration of IL-22
Time Frame: 16 weeks
|
change in serum concentration of IL-22
|
16 weeks
|
fasting triglyceride levels
Time Frame: 16 weeks
|
change in fasting triglyceride levels
|
16 weeks
|
LDL, HDL, LDL/HDL ratio
Time Frame: 16 weeks
|
change in LDL, HDL, LDL/HDL ratio
|
16 weeks
|
concentration of serum lipidome parameters (hundreds of lipid species)
Time Frame: 16 weeks
|
change in serum lipidome (hundreds of lipid species)
|
16 weeks
|
insulin secretion capacity (disposition index-2); metric parameter without defined maxima or minima; higher values indicate better insulin secretion
Time Frame: 16 weeks
|
change in insulin secretion capacity (disposition index-2); metric parameter without defined maxima or minima; higher values indicate better insulin secretion
|
16 weeks
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AGAMEMNON
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PreDiabetes
-
Mayo ClinicNot yet recruiting
-
Aga Khan UniversityLinnaeus University; Kenyatta UniversityRecruiting
-
Philip KernNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Chonbuk National University HospitalCompletedPreDiabetes
-
TNOWageningen University and Research; Google LLC.; Jumbo Supermarkten Bv.; Noldus...Completed
-
University of TorontoInternational Nut and Dried Fruit Council (INC); The National Dried Fruit Trade... and other collaboratorsUnknown
-
National Yang Ming UniversityRecruiting
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Clinical Nutrition Research Centre, SingaporeSingapore Institute for Clinical SciencesCompleted
-
Northwestern UniversityAllianceChicago; Erie Family Health CentersCompleted
Clinical Trials on Raw whole almonds
-
David BaerAlmond Board of CaliforniaCompletedHealthy | Focus: Effect of Processing on Energy Value of AlmondsUnited States
-
Integrative Skin Science and ResearchAlmond Board of CaliforniaRecruiting
-
University of TorontoCompleted
-
Integrative Skin Science and ResearchRecruitingWrinkle | Pigmentation | Collagen Degeneration | Elastic SkinUnited States
-
University of FloridaAlmond Board of CaliforniaCompleted
-
Beijing Jishuitan HospitalEnrolling by invitationFull Rotator Cuff Tear | Microfracture Procedure | Double Raw Repair | Lateral Raw RepairChina
-
United States Department of Agriculture (USDA)Almond Board of CaliforniaCompleted
-
Purdue UniversityCompletedObesity | Diabetes Mellitus, Type 2 | Appetitive BehaviorUnited States
-
Midwest Center for Metabolic and Cardiovascular...Almond Board of CaliforniaCompleted
-
Boston UniversityTufts UniversityCompletedCoronary Artery DiseaseUnited States